The Priority Review

Tag

Peanut Allergy

1 story

  1. Clinical trials

    DBV Technologies posts results of Phase 3 Viaskin Peanut study

    The REALISE study evaluated Viaskin Peanut 250 μg in 393 peanut-allergic children aged 4 to 11 years in a 6-month randomized, double-blind, placebo-controlled Phase III trial. The study began on October 25, 2016, with primary completion on September 22, 2017.